文献速递创伤与烧伤重症综合管理与镇静镇痛

脊髓损伤后静脉血栓栓塞风险:CLOTT研究的二次分析

Venous thromboembolism risk after spinal cord injury: A secondary analysis of the CLOTT study.
PubMed 文献 · J Trauma Acute Care Surg · 2022-10-07
一句话结论脊髓损伤患者48小时内启动VTE药物预防与较低血栓事件独立相关(OR 0.45),依诺肝素优于普通肝素,漏服常见。

本文为CLOTT前瞻性观察队列(2018-2020年,17家美国一级创伤中心,18-40岁)的二次分析,纳入343例住院>48小时且记录脊髓损伤的患者,评估VTE药物预防启动时机、血栓事件(DVT+PE)及漏服情况。血栓事件33例(9.6%),其中DVT 30例(8.7%)、PE 3例(0.9%)。≤48小时启动者VTE率7.1% vs >48小时12.1%(p=0.119),校正危险因素后≤48小时启动独立关联更少VTE(OR 0.45,95%CI 0.101-0.978,p=0.044)。普通肝素组VTE率21.0% vs 依诺肝素组7.5%(p=0.003)。漏服常见(29.7%),多因素分析未达显著。作者认为及时启动依诺肝素并避免漏服对限制血栓事件至关重要。

要点

  • 脊髓损伤患者血栓事件发生率高:343例中33例(9.6%),DVT 30例(8.7%)、PE 3例(0.9%)。
  • 校正危险因素后,≤48小时启动VTE药物预防独立关联更少VTE(OR 0.45,95%CI 0.101-0.978,p=0.044)。
  • 普通肝素预防者VTE率21.0%,依诺肝素预防者7.5%(p=0.003)。
  • VTE药物预防漏服常见(29.7%),多因素分析未达显著。
  • 作者认为及时启动依诺肝素并避免漏服对限制血栓事件至关重要。

适用人群与场景

  • 18至40岁、因脊髓损伤住院>48小时的患者;来自2018至2020年CLOTT前瞻性观察队列,17家美国一级创伤中心。
  • 平均±标准差年龄29.0±6.6岁,77.3%为男性,78.7%为钝性机制损伤。

处置流程与药物剂量

  • VTE药物预防启动时机:≤24小时启动者占21.3%,≤48小时启动者占49.3%。
  • 作者结论:及时启动VTE药物预防并使用依诺肝素、努力避免漏服,对限制高危患者血栓事件至关重要。

研究设计与关键结果

  • 研究类型:CLOTT前瞻性观察队列的二次分析;样本量343例脊髓损伤患者;17家美国一级创伤中心;人群18至40岁、住院>48小时。
  • 主要终点VTE(DVT+PE)共33例(9.6%):DVT 30例(8.7%),PE 3例(0.9%)。
  • ≤48小时启动VTE药物预防者VTE率7.1% vs >48小时启动者12.1%(p=0.119)。
  • 校正队列间危险因素差异后,≤48小时启动独立关联更少VTE(OR 0.45,95%CI 0.101-0.978,p=0.044)。
  • 普通肝素预防者VTE率21.0% vs 依诺肝素预防者7.5%(p=0.003)。
  • VTE药物预防漏服常见(29.7%),与血栓事件增加相关,但多因素分析未达显著。

证据类型、等级与局限

  • 证据类型:前瞻性观察队列研究的二次分析;证据等级:预后与流行病学,Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对脊髓损伤患者及时启动VTE药物预防并使用依诺肝素、努力避免漏服,对限制血栓事件至关重要。
  • ≤48小时启动VTE药物预防在校正后独立关联更少VTE(OR 0.45,95%CI 0.101-0.978,p=0.044);未校正时≤48小时组7.1% vs >48小时组12.1%(p=0.119)。
  • 普通肝素预防者VTE率21.0%,依诺肝素预防者7.5%(p=0.003)。
  • VTE药物预防漏服常见(29.7%),多因素分析未达显著。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Patients with spinal cord injury (SCI) are at high risk of venous thromboembolism (VTE). Pharmacologic VTE prophylaxis (VTEppx) is frequently delayed in patients with SCI because of concerns for bleeding risk. Here, we hypothesized that delaying VTEppx until >48 hours would be associated with increased risk of thrombotic events.

METHODS: This is a secondary analysis of the 2018 to 2020 prospective, observational, cohort Consortium of Leaders in the Study of Traumatic Thromboembolism (CLOTT) study of patients aged 18 to 40 years, at 17 US level 1 trauma centers. Patients admitted for >48 hours with documented SCI were evaluated. Timing of initiation of VTEppx, rates of thrombotic events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and missed VTEppx doses were analyzed. The primary outcome was VTE (DVT + PE).

RESULTS: There were 343 patients with SCI. The mean ± SD age was 29.0 ± 6.6 years, 77.3% were male, and 78.7% sustained blunt mechanism. Thrombotic events occurred in 33 patients (9.6%): 30 DVTs (8.7%) and 3 PEs (0.9%). Venous thromboembolism prophylaxis started at ≤24 hours in 21.3% of patients and 49.3% at ≤48 hours. The rate of VTE for patients started on VTEppx ≤48 hours was 7.1% versus 12.1% if started after 48 hours ( p = 0.119). After adjusting for differences in risk factors between cohorts, starting ≤48 hours was independently associated with fewer VTEs (odds ratio, 0.45; 95% confidence interval, 0.101-0.978; p = 0.044). Unfractionated heparin was associated with a VTE rate of 21.0% versus 7.5% in those receiving enoxaparin as prophylaxis ( p = 0.003). Missed doses of VTEppx were common (29.7%) and associated with increased thrombotic events, although this was not significant on multivariate analysis.

CONCLUSION: Rates of thrombotic events in patients with SCI are high. Prompt initiation of VTEppx with enoxaparin and efforts aimed at avoiding missed doses are critical to limit thrombotic events in these high-risk patients.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Godat LN, Haut ER, Moore EE, et al. Venous thromboembolism risk after spinal cord injury: A secondary analysis of the CLOTT study. J Trauma Acute Care Surg. 2022. PMID: 36203245. doi:10.1097/TA.0000000000003807

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。